drugset / Trial / NCT03159897
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
RandomizedParallel-groupOpen-labelTreatment
Summary
The FIL-Rouge is a randomized, open-label, multicenter, phase III, 2-arm study. The primary objective is to compare efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL).
Timeline
- Start
- 2017-08-01
- Primary completion
- 2021-11-02
- Completion
- 2024-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | 10000 unknown | Intravenous |
| Subject | Dacarbazine | Small molecule | 375 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 35 mg/m2 | Intravenous |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |